ANPA-0073 is under clinical development by Schrodinger and currently in Phase I for Pulmonary Arterial Hypertension. According to GlobalData, Phase I drugs for Pulmonary Arterial Hypertension have an 85% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ANPA-0073’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ANPA-0073 overview
ANPA-0073 is under development for the treatment of pulmonary arterial hypertension (PAH) and selective weight loss obesity. It is administered through oral route in the form of capsules. The drug candidate acts by targeting apelin receptor (APJR) and is being developed based on the Schrodinger artificial intelligence (AI) technology.
The drug candidate was under development for the treatment of idiopathic pulmonary fibrosis (IPF).
Schrodinger overview
Schrodinger is a healthcare technology company that provides software solutions for drug discovery. The company offers a computational platform designed with predictive modeling, data analytics and collaboration applicable to molecular discovery. Its pipeline products include SGR-1505 (MALT1) against non-Hodgkin’s lymphoma, SGR-2921 (CDC7) to treat hematological cancers and solid tumors and SGR-3515 (Wee1) for gynecological cancers, and LRRK2 for Neurology and SOS1 for cancers and others. Schrodinger‘s other products include small molecule products, biological drug discovery and material science products. It provides training, documentation and support services. The company operates through offices in the US, Germany, Japan, Ireland, the UK, India, China and South Korea. Schrodinger is headquartered in New York City, New York, the US.
For a complete picture of ANPA-0073’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
